Breast Cancer and Skin Cancer Unit of the IOB Institute of Oncology
• Prior to joining this team, he worked for more than three years in the melanoma and breast cancer unit of the Vall d’Hebrón University Hospital and the Vall d’Hebrón Institute of Oncology (VHIO), where he participated as a researcher in numerous studies in phase 1, 2 and 3, both in breast and in melanoma, some of which have led to the approval of new medicines in new indications.
• The main areas of interest of Dr. Soberino focus on the field of breast cancer in endocrine treatment, collaborating in studies aimed at overcoming resistance to hormonal therapy that may occur during both adjuvant treatment and metastatic disease. In this sense, he has participated in the trials that led to the approval of the cdk4-6 palbociclib and ribociclib inhibitors in the first line of metastatic breast cancer, as well as in the trials under development for adjuvant disease.
• In the field of melanoma, his main field of interest focuses on treatment with immunotherapy. In this field he participated in the studies that led to the approval of Pembrolizumab in the first line of metastatic melanoma, and in the combination of Nivolumab with Ipilimumab, both being treatments that revolutionised the treatment of this disease. Currently, he actively collaborates with other groups to promote the development of new medicines to help improve outcomes in this group of patients.